Table 1.
Participant characteristics by country
| Variables | Australia n = 20 | Brazil n = 20 | France n = 30 | Total N = 70 |
|---|---|---|---|---|
| Demographic factors | ||||
| Male Sex | 17 (85.0) | 6 (30.0) | 21 (70.0) | 44 (62.9) |
| Age | 48.7 (6.0) | 51.8 (9.4) | 50.45 (9.7) | 50.3 (8.5) |
| Weight (kg) | 83.0 (19.9) | 66.8 (15.4) | 70.5 (13.4) | 73.0 (17.1) |
| Married/partner | 5 (25.0) | 11 (55.0) | 17 (56.7) | 33 (47.1) |
| Ethnicity Caucasian | 18 (90.0) | 12 (60.0) | 23 (82.1) | 53 (75.7) |
| Living alone | 7 (35.0) | 2 (10.0) | 9 (30.0) | 18 (25.7) |
| Living with children | 4 (20) | 10 (50.0) | 14 (46.6) | 25 (35.7) |
| Education ≥ university | 3 (15.0) | 4 (20.0) | 7 (23.3) | 14 (20.0) |
| Employmenta | 12 (60.0) | 6 (30.0) | 20 (68.9) | 48 (69.6) |
| Current smoker | 12 (60.0) | 7 (35.0) | 15 (50.0) | 34 (48.6) |
| Alcohol last month | 15 (75.0) | 5 (25.0) | 13 (44.8) | 33 (47.8) |
| Past history of Injecting drugs | 17 (85.0) | 3 (15.8) | 14 (48.3) | 34 (50.0) |
| Treatmentb | ||||
| Past history | 5 (26.3) | 2 (10.0) | 17 (58.6) | 24 (35.3) |
| Current | 14 (70.0) | 15 (75.0) | 13c (46.4) | 42 (61.8) |
| Pill burden (total number) | 8.1 (6.3) | 8.2 (4.8) | 9.0 (5.4) | 8.5 (5.4) |
| Antidepressant drugs | 7 (35.0) | 12 (60.0) | 5 (16.7) | 24 (34.3) |
| Antianxiety drugs | 5 (20.0) | 4 (20.0) | 4 (13.3) | 13 (18.6) |
| Sedative drugs | 4 (20.0) | 0 (0.0) | 5 (17.9) | 9 (13.4) |
| Clinical factors | ||||
| Time since diagnosis (years) | 5.0 (13.8) | 3.5 (4.5) | 8.0 (10.3) | 5.0 (10.0) |
| HIV-Coinfection | 5 (29.4) | 5 (27.8) | 4 (26.8) | 14 (28.0) |
| Depression, self-reported (past month) | 11 (55.0) | 10 (50.0) | 12 (41.4) | 33 (47.8) |
| Symptoms (total number) | 12.0 (7.0) | 15.0 (13.5) | 12.5 (6.0) | 13.0 (7.0) |
aInclusive of full time and part time work; bBoth interferon alpha and pegylated in combination with ribavirin; c8 patients (32 %) receiving directly acting antiviral drugs
Data are summarised as count (percentage) for categorical variables, and mean (SD) for numerical variables